• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人源仅重链抗体的晶体结构与表征揭示了一种类似于单克隆抗体的新型稳定二聚体结构。

Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies.

作者信息

Mieczkowski Carl, Bahmanjah Soheila, Yu Yao, Baker Jeanne, Raghunathan Gopalan, Tomazela Daniela, Hsieh Mark, McCoy Mark, Strickland Corey, Fayadat-Dilman Laurence

机构信息

Discovery Biologics, Protein Sciences, Merck & Co., Inc., South San Francisco, CA 94080, USA.

Department of Chemistry, Modeling and Informatics, Merck & Co., Inc., Kenilworth, NJ 07033, USA.

出版信息

Antibodies (Basel). 2020 Nov 22;9(4):66. doi: 10.3390/antib9040066.

DOI:10.3390/antib9040066
PMID:33266498
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7709113/
Abstract

We report the novel crystal structure and characterization of symmetrical, homodimeric humanized heavy-chain-only antibodies or dimers (HC2s). HC2s were found to be significantly coexpressed and secreted along with mAbs from transient CHO HC/LC cotransfection, resulting in an unacceptable mAb developability attribute. Expression of full-length HC2s in the absence of LC followed by purification resulted in HC2s with high purity and thermal stability similar to conventional mAbs. The V and C1 portion of the heavy chain (or Fd) was also efficiently expressed and yielded a stable, covalent, and reducible dimer (Fd2). Mutagenesis of all heavy chain cysteines involved in disulfide bond formation revealed that Fd2 intermolecular disulfide formation was similar to Fabs and elucidated requirements for Fd2 folding and expression. For one HC2, we solved the crystal structure of the Fd2 domain to 2.9 Å, revealing a highly symmetrical homodimer that is structurally similar to Fabs and is mediated by conserved (C1) and variable (V) contacts with all CDRs positioned outward for target binding. Interfacial dimer contacts revealed by the crystal structure were mutated for two HC2s and were found to dramatically affect HC2 formation while maintaining mAb bioactivity, offering a potential means to modulate novel HC2 formation through engineering. These findings indicate that human heavy-chain dimers can be secreted efficiently in the absence of light chains, may show good physicochemical properties and stability, are structurally similar to Fabs, offer insights into their mechanism of formation, and may be amenable as a novel therapeutic modality.

摘要

我们报告了对称的、同型二聚体人源化仅重链抗体或二聚体(HC2)的新型晶体结构及表征。发现HC2与单克隆抗体(mAb)从瞬时CHO重链/轻链共转染中显著共表达并分泌,导致mAb的可开发性属性不可接受。在无轻链的情况下全长HC2的表达随后进行纯化,得到了具有与传统mAb相似的高纯度和热稳定性的HC2。重链的V和C1部分(或Fd)也有效表达并产生了稳定的、共价的且可还原的二聚体(Fd2)。对参与二硫键形成的所有重链半胱氨酸进行诱变,结果表明Fd2分子间二硫键的形成与Fab相似,并阐明了Fd2折叠和表达的要求。对于一种HC2,我们将Fd2结构域的晶体结构解析到2.9 Å,揭示了一种高度对称的同型二聚体,其结构与Fab相似,由保守(C1)和可变(V)接触介导,所有互补决定区(CDR)向外定位用于靶标结合。晶体结构揭示的界面二聚体接触针对两种HC2进行了突变,发现其显著影响HC2的形成,同时保持mAb的生物活性,这为通过工程手段调节新型HC2的形成提供了一种潜在方法。这些发现表明,人重链二聚体在无轻链的情况下可有效分泌,可能具有良好的物理化学性质和稳定性,在结构上与Fab相似,为其形成机制提供了见解,并且可能适合作为一种新型治疗方式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/481ef480707f/antibodies-09-00066-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/35780947b004/antibodies-09-00066-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/066e6d3ccdb9/antibodies-09-00066-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/b4cc237bc264/antibodies-09-00066-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/de7ab7578edc/antibodies-09-00066-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/906abf3b7214/antibodies-09-00066-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/c96895747719/antibodies-09-00066-g006a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/96a2a799cb93/antibodies-09-00066-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/481ef480707f/antibodies-09-00066-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/35780947b004/antibodies-09-00066-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/066e6d3ccdb9/antibodies-09-00066-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/b4cc237bc264/antibodies-09-00066-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/de7ab7578edc/antibodies-09-00066-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/906abf3b7214/antibodies-09-00066-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/c96895747719/antibodies-09-00066-g006a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/96a2a799cb93/antibodies-09-00066-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46d/7709113/481ef480707f/antibodies-09-00066-g008.jpg

相似文献

1
Crystal Structure and Characterization of Human Heavy-Chain Only Antibodies Reveals a Novel, Stable Dimeric Structure Similar to Monoclonal Antibodies.人源仅重链抗体的晶体结构与表征揭示了一种类似于单克隆抗体的新型稳定二聚体结构。
Antibodies (Basel). 2020 Nov 22;9(4):66. doi: 10.3390/antib9040066.
2
Comparing domain interactions within antibody Fabs with kappa and lambda light chains.比较抗体Fabs中κ链和λ链的结构域相互作用。
MAbs. 2016 Oct;8(7):1276-1285. doi: 10.1080/19420862.2016.1214785. Epub 2016 Jul 25.
3
"BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.“双特异性抗体”:在瞬时转染的哺乳动物细胞中生产IgG形式的双特异性抗体
Methods Mol Biol. 2019;1904:431-454. doi: 10.1007/978-1-4939-8958-4_22.
4
Antibody engineering to improve manufacturability.抗体工程以提高可制造性。
Protein Expr Purif. 2018 Sep;149:75-83. doi: 10.1016/j.pep.2018.04.003. Epub 2018 Apr 12.
5
IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design.重链二聚体的不依赖IgG轻链分泌:对治疗性抗体生产和设计的影响
Biochem J. 2017 Sep 7;474(18):3179-3188. doi: 10.1042/BCJ20170342.
6
Improvement of heavy and light chain assembly by modification of heavy chain constant region 1 (CH1): Application for the construction of an anti-paclitaxel fragment antigen-binding (Fab) antibody.通过修饰重链恒定区 1(CH1)改善重链和轻链组装:在构建抗紫杉醇片段抗原结合(Fab)抗体中的应用。
J Biotechnol. 2018 Dec 20;288:41-47. doi: 10.1016/j.jbiotec.2018.10.009. Epub 2018 Oct 31.
7
Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.单克隆抗体减粘突变体的合理设计:疏水与静电分子间相互作用
MAbs. 2015;7(1):212-30. doi: 10.4161/19420862.2014.985504.
8
On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells.关于用于CHO细胞高效重组抗体生产的重链与轻链基因的最佳比例
Biotechnol Prog. 2005 Jan-Feb;21(1):122-33. doi: 10.1021/bp049780w.
9
Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody.氢交换质谱揭示了IgG1单克隆抗体可逆自缔合过程中的蛋白质界面和远距离动态偶联效应。
MAbs. 2015;7(3):525-39. doi: 10.1080/19420862.2015.1029217.
10
Characterization and Modeling of Reversible Antibody Self-Association Provide Insights into Behavior, Prediction, and Correction.可逆抗体自缔合的表征与建模为行为、预测和校正提供了见解。
Antibodies (Basel). 2021 Feb 15;10(1):8. doi: 10.3390/antib10010008.

引用本文的文献

1
The dispensability of V-V pairing and the indispensability of V domain integrity in the IgG1 secretion process.在IgG1分泌过程中V-V配对的可缺失性及V结构域完整性的不可或缺性。
Front Mol Biosci. 2024 May 2;11:1346259. doi: 10.3389/fmolb.2024.1346259. eCollection 2024.
2
Blueprint for antibody biologics developability.抗体生物制剂开发蓝图。
MAbs. 2023 Jan-Dec;15(1):2185924. doi: 10.1080/19420862.2023.2185924.
3
Design, Production, Characterization, and Use of Peptide Antibodies.肽抗体的设计、生产、表征及应用

本文引用的文献

1
Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.通过早期发现筛选预测抗体可开发性特征。
MAbs. 2020 Jan-Dec;12(1):1743053. doi: 10.1080/19420862.2020.1743053.
2
Five computational developability guidelines for therapeutic antibody profiling.五项治疗性抗体分析的计算可开发性指南。
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4025-4030. doi: 10.1073/pnas.1810576116. Epub 2019 Feb 14.
3
Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook.骆驼科单域抗体:历史回顾与未来展望
Antibodies (Basel). 2023 Jan 13;12(1):6. doi: 10.3390/antib12010006.
Front Immunol. 2017 Nov 20;8:1589. doi: 10.3389/fimmu.2017.01589. eCollection 2017.
4
IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design.重链二聚体的不依赖IgG轻链分泌:对治疗性抗体生产和设计的影响
Biochem J. 2017 Sep 7;474(18):3179-3188. doi: 10.1042/BCJ20170342.
5
Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.用于表达完全IgG双特异性抗体的特定重链/κ轻链界面的计算设计。
Protein Sci. 2017 Oct;26(10):2021-2038. doi: 10.1002/pro.3240. Epub 2017 Jul 31.
6
Applications of Yeast Surface Display for Protein Engineering.酵母表面展示技术在蛋白质工程中的应用
Methods Mol Biol. 2015;1319:155-75. doi: 10.1007/978-1-4939-2748-7_8.
7
Alternative molecular formats and therapeutic applications for bispecific antibodies.双特异性抗体的替代分子形式及治疗应用
Mol Immunol. 2015 Oct;67(2 Pt A):95-106. doi: 10.1016/j.molimm.2015.01.003. Epub 2015 Jan 27.
8
Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy.重链抗体:HER2+乳腺癌个体化治疗的新范例。
Bioimpacts. 2013;3(1):1-4. doi: 10.5681/bi.2013.009. Epub 2013 Jan 27.
9
Nanobodies: natural single-domain antibodies.纳米抗体:天然单域抗体。
Annu Rev Biochem. 2013;82:775-97. doi: 10.1146/annurev-biochem-063011-092449. Epub 2013 Mar 13.
10
Germline VH/VL pairing in antibodies.抗体中的种系 VH/VL 配对。
Protein Eng Des Sel. 2012 Oct;25(10):523-9. doi: 10.1093/protein/gzs043. Epub 2012 Jul 15.